- Home
- NUW vs NBTX Comparison
NUW vs NBTX Comparison
Compare NUW & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- NBTX
- Stock Information
- Founded
- NUW 2008
- NBTX 2003
- Country
- NUW United States
- NBTX France
- Employees
- NUW N/A
- NBTX N/A
- Industry
- NUW Investment Managers
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- NUW Finance
- NBTX Health Care
- Exchange
- NUW Nasdaq
- NBTX Nasdaq
- Market Cap
- NUW 248.3M
- NBTX 201.9M
- IPO Year
- NUW N/A
- NBTX 2020
- Fundamental
- Price
- NUW $13.93
- NBTX $3.75
- Analyst Decision
- NUW
- NBTX Strong Buy
- Analyst Count
- NUW 0
- NBTX 1
- Target Price
- NUW N/A
- NBTX $12.00
- AVG Volume (30 Days)
- NUW 45.3K
- NBTX 8.9K
- Earning Date
- NUW 01-01-0001
- NBTX 09-18-2024
- Dividend Yield
- NUW 3.66%
- NBTX N/A
- EPS Growth
- NUW N/A
- NBTX N/A
- EPS
- NUW N/A
- NBTX N/A
- Revenue
- NUW N/A
- NBTX $45,220,186.00
- Revenue This Year
- NUW N/A
- NBTX N/A
- Revenue Next Year
- NUW N/A
- NBTX N/A
- P/E Ratio
- NUW N/A
- NBTX N/A
- Revenue Growth
- NUW N/A
- NBTX 526.17
- 52 Week Low
- NUW $12.45
- NBTX $2.76
- 52 Week High
- NUW $14.44
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- NUW 66.64
- NBTX 53.25
- Support Level
- NUW $13.72
- NBTX $3.60
- Resistance Level
- NUW $13.85
- NBTX $3.95
- Average True Range (ATR)
- NUW 0.05
- NBTX 0.19
- MACD
- NUW 0.01
- NBTX -0.01
- Stochastic Oscillator
- NUW 100.00
- NBTX 38.18
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.